Review article: Approaches to Barrett's oesophagus treatment - The role of proton pump inhibitors and other interventions

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 19, Issue 1, 2004, Pages 54-59

  Jankowski, J ^a   Sharma, P ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ACID SUPPRESSIVE THERAPY; ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CATHETER ABLATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSE RESPONSE; ENDOSCOPIC SURGERY; ESOPHAGITIS; ESOPHAGUS SURGERY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THERAPY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HUMANS; PHOTOCHEMOTHERAPY; PROTON PUMPS;

EID: 1342289063     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-53.
2. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368-78.
3. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-37.
4. Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001; 234: 532-8.
5. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122(3): 633-40.
6. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001; 96: 3071-83.
7. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patients subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96: 2839-48.
8. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34: 257-63.
9. Wong DJ, Paulson TG, Prevo LJ, et al. p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001; 61: 8284-9.
10. Zentilin P, Conio M, Mele MR, et al. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment Pharmacol Ther 2002; 16: 893-8.
11. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-96.
12. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal cancer. N Engl J Med 1999; 340: 825-31.
13. Corley D, Levin TR, Habel L, Buffler P. Esophageal metaplasia to adenocarcinoma: A population-based natural history. Gastroenterology 2003; 124: A-635 (Abstract #W1271).
14. Cheong E, Igali L, Harvey I, et al. Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther 2003; 17: 379-86.
15. Buttar NS, Wang KK, Leontovich O, et al. Chemopreventlon of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-12.
16. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's esophagus during omeprazole treatment: a randomized double-blind study. Gut 1999; 45: 489-94.
17. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35.
18. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003; 52(2): 174-80.
19. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001; 96: 331-7.
20. Sharma P, Reker D, Weston A, et al. Normalization of intraesophageal pH in patients with Barrett's esophagus (BE) on rabeprazole & relationship of pH to Barrett's length and hiatal hernia. Am J Gastroenterol 2002; 97: 128 (Abstract #4).
21. Sharma P, Sampliner RE, Carmargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
22. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7(6): 623-8.
23. Malesci A, Savarino V, Xentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44(6): 700-5.
24. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89(10): 1844-8.
25. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12(9): 893-7.
26. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002; 39: 6071-81.
27. Corley DA, Kerlikowski K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124; 47-56.
28. Ye W, Chow WH, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patient with gastroesophageal reflux disease and after antireflux surgery. Gastroenterology 2001; 121: 1286-93.
29. Freston JW, Triadafilopoulos G. Review article: approaches to the long-term management of adults with GERD - proton pump inhibitor therapy, laparoscopic fundoplication, or endoscopic therapy. Aliment Pharmacol Ther 2004; 19(Suppl 1): 35-42.
30. Overholt BF, Lightdale CJ, Wang K, et al. International, multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using pofimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): Results of 24-month follow-up. Gastroenterology 2003; 124: A-20 (Abstract #151).
31. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia In Barrett's esophagus. Gastroenterology 2000; 118: 670-7.